Patents by Inventor Simon GRASSMANN

Simon GRASSMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CXCR6-transduced T cells for targeted tumor therapy
    Patent number: 11723922
    Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 15, 2023
    Assignee: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN
    Inventors: Sebastian Kobold, Stefan Endres, Moritz Rapp, Simon Grassmann
  • CXCR6-TRANSDUCED T CELLS FOR TARGETED TUMOR THERAPY
    Publication number: 20180256645
    Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.
    Type: Application
    Filed: October 14, 2016
    Publication date: September 13, 2018
    Inventors: Sebastian KOBOLD, Stefan ENDRES, Moritz RAPP, Simon GRASSMANN